Results 1 to 10 of about 29,949 (204)

Development of Lipid–Polymer Hybrid Nanoparticles for Improving Oral Absorption of Enoxaparin

open access: yesPharmaceutics, 2020
Enoxaparin, an anticoagulant that helps prevent the formation of blood clots, is administered parenterally. Here, we report the development and evaluation of lipid–polymer hybrid nanoparticles (LPHNs) for the oral delivery of enoxaparin.
Bo Tang, Guihua Fang
exaly   +4 more sources

Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolic events in Women Undergoing Surgery for Gynecologic Cancers: A Randomized Clinical Trial Study [PDF]

open access: yesIranian Journal of Nursing and Midwifery Research
Background: Venous thromboembolism (VTE), encompassing deep venous thrombosis and pulmonary embolism, presents a significant clinical risk for women undergoing surgical intervention for gynecologic malignancies. Enhanced prophylactic strategies are vital
Fariba Behnamfar   +4 more
doaj   +3 more sources

Enoxaparin induces apoptosis and autophagy, modulates inflammatory signaling, and reduces oxidative DNA damage in breast and liver cancer cells [PDF]

open access: yesScientific Reports
Cancer progression involves intricate interactions between inflammatory signaling, programmed cell death mechanisms, and oxidative stress. Although enoxaparin is widely used for managing cancer-associated thrombosis, its direct cellular effects on tumor ...
Sedat Carkit   +5 more
doaj   +2 more sources

Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial.

open access: yesPLoS ONE, 2023
Cancer and/or major surgery are two factors that predispose to post-operative thrombosis. The annual incidence of venous thromboembolic disease (VTED) in cancer patients was estimated at 0.5%-20%.
Chadli Dziri   +7 more
doaj   +1 more source

Admission thrombelastography does not guide dose adjustment of enoxaparin in trauma patients

open access: yesSurgery Open Science, 2020
Background: Enoxaparin is used as chemoprophylaxis to reduce incidence of venous thromboembolism and its complications following trauma. Serum anti-Xa monitoring is used to assess efficacy but requires several doses to be administered. Thrombelastography
Hannah V. Hayes   +5 more
doaj   +1 more source

The effects of enoxaparin on the liver in experimental pneumoperitoneum model [PDF]

open access: yesActa Cirúrgica Brasileira, 2016
PURPOSE: To investigate the potential protective effects of enoxaparin against the adverse events of carbon dioxide (CO2) pneumoperitoneum. METHODS: Thirty four rats were divided into three groups: Group 1 (sham) underwent insertion of Veress needle ...
Turgut Cavusoglu   +9 more
doaj   +2 more sources

The Impact of Continuous Veno-Venous Hemodiafiltration on the Efficacy of Administration of Prophylactic Doses of Enoxaparin: A Prospective Observational Study

open access: yesPharmaceuticals, 2023
Background: Critically ill patients frequently require continuous renal replacement therapy (CRRT). During CRRT, particles up to 10 kDa in size, such as enoxaparin, may be removed. The aim of this study was to determine if patients receiving prophylactic
Aleksander Aszkiełowicz   +4 more
doaj   +1 more source

Cell-Penetrating Peptide-Surface Modified Liposomes to Enhance the Intestinal Absorption of Enoxaparin [PDF]

open access: yesPharmaceutical Sciences, 2023
Background: Enoxaparin is low-molecular-weight heparin administered by subcutaneous/intravenous injection. The oral bioavailability of enoxaparin is restricted by its low absorption through the intestine.
Hessam Rostamian   +4 more
doaj   +1 more source

Characterizing the delays in adequate thromboprophylaxis after TBI

open access: yesTrauma Surgery & Acute Care Open, 2021
Background We sought to compare enoxaparin dosing for venous thromboembolism (VTE) prophylaxis in trauma patients with and without traumatic brain injury (TBI) to better understand the time and dose required to reach target anti-Xa levels. Our hypothesis
Eric J Ley   +6 more
doaj   +1 more source

Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study

open access: yesEClinicalMedicine, 2020
Background: Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection is associated with hypercoagulability caused by direct invasion of endothelial cells and/or proinflammatory cytokine release.
Filippo Albani   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy